Bromide

Bromide

SCHEMBL6095818

Br.Br.Br.Br.Br.Br.Br.Br.Br.Br

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 1.00
CA2 P00918 1/20 1.00
CA4 P22748 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1872791 1.00
Bromide SCHEMBL597803 1.00
Bromide SCHEMBL8358501 1.00
Bromide SCHEMBL1061497 1.00
Bromide SCHEMBL22734108 1.00
Bromide SCHEMBL57402 1.00
Bromide SCHEMBL16618 1.00
Bromide SCHEMBL41784 1.00
Bromide SCHEMBL183 1.00
Bromide SCHEMBL29362293 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114127211-B Method for improving barrier film removal rate in bulk tungsten slurry CMC材料有限责任公司 2024-06-25 CN disclosed
CN-114620750-B Process for extracting lithium from sodium sulfate subtype salt lake brine 中蓝长化工程科技有限公司 2023-10-27 CN disclosed
CN-116903164-A Near-zero emission system and method for high-salt-content high-concentration organic matter industrial wastewater 中煤能源研究院有限责任公司 2023-10-20 CN disclosed
CN-112639003-B Inhibition of aryl cleavage in aryl-functional polysiloxanes 美国陶氏有机硅公司 2023-08-11 CN disclosed
US-20060276444-A1 Porphyrin-polyamine conjugates for cancer therapy PROGEN PHARMACEUTICALS, INC. 2006-12-07 US disclosed
US-7026347-B2 Porphyrin-polyamine conjugates for cancer therapy CELLGATE, INC. (US) 2006-04-11 US disclosed
EP-1515973-A1 PORPHYRIN-POLYAMINE CONJUGATES FOR CANCER THERAPY Cellgate Inc. (US) 2005-03-23 EP disclosed
US-20040152687-A1 Porphyrin-polyamine conjugates for cancer therapy CELLGATE, INC. 2004-08-05 US disclosed
WO-2004002991-A1 PORPHYRIN-POLYAMINE CONJUGATES FOR CANCER THERAPY CELLGATE, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276444-A1 Porphyrin-polyamine conjugates for cancer therapy SRM, PAICS, FOLH1 CA1 3732/4885CA2 4274/4885CA4 4499/4885
US-20040152687-A1 Porphyrin-polyamine conjugates for cancer therapy SRM, PAICS, FOLH1 CA1 3732/4885CA2 4274/4885CA4 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.